Immunology (IGG)

IrsiCaixa collaborator researchers: Erola Ainsua Enrich, Mª Luisa Rodríguez de la Concepción, Núria Pedreño López, Julià Blanco Arbués, Nuria Izquierdo Useros, Julia García Prado, Rosina Malagrida Escalas

IrsiCaixa collaborator researchers: Mª Luisa Rodríguez de la Concepción, Núria Pedreño López, Erola Ainsua Enrich.

The majority of SARS-CoV-2 infected individuals develop mild symptoms, but about 10-30% can develop a severe disease that requires hospitalization and, eventually, the admission into the intensive care unit (ICU). Although it is not clear which factors determine the development of this severe form of the disease, it has been postulated that a deregulated response by the body’s defenses against the infection might be behind the hyperinflammation and tissue damage observed in those patients.

Codi: 101046118